BioBuzz CEO and founder Chris Frew discusses the complex biotech sector and the hopeful signs that it is getting ready to blossom once again.

Read more: Are new hiring models helping thaw the biotech winter?

Pharma, biotech and cell & gene companies who use Werum PAS-X MES as well as those who are interested in the use of manufacturing IT and manufacturing intelligence to digitise their production are invited to Connext 2021 – the new virtual Pharma Software Summit by Werum Solutions.

With Covid-19 vaccine delivery highlighting the need for resilience in pharma and biotech supply chains, Karl H. Lauri, managing team member at MRPeasy.com, explains that ERP/MRP gives smaller suppliers the backbone required to take part.

A UK-backed biotech company has achieved a pioneering biocomputer breakthrough which is accelerating the development and manufacture of cheaper drugs and vaccines.

AI knowledge combined with gene-editing precision opens the way to dial-a-protein.

Location: Electronic Resource- 

Location: Electronic Resource- 

Location: Engineering Library- R857.M3S853 2016

February’s international symposium, entitled “The role of agricultural biotechnologies in sustainable food systems and nutrition”, will explore how the application of science and technology, and particularly agricultural biotechnologies, can benefit [...]

AstraZeneca will set up a R&D centre and an AI innovation centre in Shanghai, as well as create a $1bn fund that would invest in healthcare start-ups.

Scientific innovation, a conducive regulatory climate and increased globalisation of drug markets are driving an investment boom in biotechnology, with small companies and emerging markets shaking up the sector.

Global FDI in the biotechnology sector has witnessed year-on-year increase since 2015.

Indian pharma and biotech companies are confident that under the new US President Donald Trump, its strengths in high quality generics manufacture and export will continue to command respect. This view is

Venture creation in biotech is witnessing a sustained contraction. After the pandemic bubble’s over-indulgence, the venture ecosystem appears to have reset its pace of launching new startups. According to the latest Pitchbook data, venture creation in biotech hit its slowest

The post The Biotech Startup Contraction Continues… And That’s A Good Thing appeared first on LifeSciVC.

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC From the outside, one might assume all biotech venture capital (VC) firms are more similar than different. However, once you look under the

The post A Primer on Early-Stage Biotech VC appeared first on LifeSciVC.

By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC Greetings from Lake Winnipesaukee in NH where I am at this time every year. It’s midsummer and vacation time for me and the

The post A Biotech Midsummer’s Madness appeared first on LifeSciVC.

Today’s market likes products. Platforms aren’t in vogue anymore. Investors, especially in the public markets, only want late stage de-risked assets. Pharma only seems to be buying these kinds of asset. VCs need to focus on clinical stage companies. Or

The post Biotech Risk Cycles: Assets And Platforms appeared first on LifeSciVC.

We’re seeing an alarming increase in the number of failed biotech companies. While the biotechnology industry holds enormous […]

The Amgen Biotech Experience empowers teachers to bring biotechnology into their classrooms to spark students� love of science and features a hands-on curriculum that introduces students to the excitement of scientific discovery.

Bharat Biotech announced the release of an medlinkoral cholera vaccine/medlink (OCV), a significant public health issue in regions with inadequate sanitation (!--ref1--).

Highlights: Advances in genetic engineering have paved way for the development of living cell diagnostics and the

Amgen Scientists Visit Biotechnology Classrooms Across the Country in Support of National Lab Day

Bengaluru-based biotech firm, Pandorum Technologies, has announced that it has developed artificial living tissue using 3D printing which performs the function of a human liver.

Vaccine also offers 65% protection against Delta variant, according to firm

Industry experts call for support to firms pursuing cutting-edge technologies as they forge ahead 

Some of the experiments being mooted include how weightlessness can influence muscle loss on those in space, what kind of algae may be suitable as nutrients or to preserve food for longer

Funds from the Gates Foundation and U.K. government will help address antimicrobial resistance in low- and middle-income countries

Funds from the Gates Foundation and U.K. government will help address antimicrobial resistance in low- and middle-income countries

After years of heady expansion, sector is feeling growing pains

Stock market conditions are favorable for Chinese technology firms

The vaccine will be developed using the virus strain isolated at the ICMR#39;s National Institute of Virology (NIV), Pune, a statement said.

1. ICMR, National Institute Of Virology Join Hands With Hyderabad Based Biotech Firm To Develop COVID-19 Vaccine  Swarajya
2. India to develop ‘fully indigenous’ Covid vaccine as ICMR partners with Bharat Biotech  ThePrint
3. ICMR teams up with Bharat Biotech to develop Covid-19 vaccine  Times of India
4. ICMR joins with Hyderabad firm to develop COVID-19 vaccine  Northeast Now
5. Covid-19 patients with mild symptoms don't need hospitalization: Health ministry's revised discharge policy  Livemint
6. View Full coverage on Google News

The OECD and the ESRC Genomics Policy & Research Forum jointly organised a one-day Forum on 12 November 2012 in Paris. The event was both retrospective and forward-looking. The forum concluded that the promise of biotechnology is not set but evolves with fresh scientific knowledge, novel laws and regulations. The future of biotechnology needs to also integrate social and cultural dimensions.

This book discusses scientific and technological tools at the centre of a renewed interest in marine biotechnology that is contributing to a new bioeconomy sector in many countries and offering potential new solutions to global challenges.

This newsletter provides up-to-date information on activities related to biotechnology at the Organisation for Economic Co-operation and Development (OECD). It is mainly intended for delegates to OECD meetings who are already familiar with certain aspects of OECD‟s work. We hope that it is also informative for the wider biotech community.

OECD major events and activities relating to biotechnologies: latest developments are updated biannually in this Newsletter

A major fruit crop of temperate regions, APPLE is consumed worldwide as fresh fruit, juice and other food products. This consensus document provides science-based key insights for the regulatory assessment of the environmental safety of genetically-engineered products: taxonomy, reproductive biology, genetics, hybridisation and introgression, and ecology.

There's been plenty of head-scratching over at Omega Diagnostics, one of the biotech minnows whose share price has shot up on the back of its efforts to tackle the pandemic.

The vaccine will be developed using the virus strain isolated at the ICMR's National Institute of Virology (NIV), Pune, a statement said.

Virus strain from NIV Pune transferred.

Source: Streetwise Reports   05/06/2020

In a May 4 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Arcturus Therapeutics Holdings Inc. (ARCT:NASDAQ) formed a partnership with Catalent Inc. (CTLT:NYSE), which "raises the profile of LUNAR-COV19 as a leading vaccine candidate."

Arce reviewed Catalent's contribution to the partnership. The global contract development and manufacturing organization is to manufacture Arcturus' messenger RNA (mRNA) LUNAR-COV19 for protection against SARS-CoV-2 to be used first for human clinical trials and potentially, eventually commercially.

As for timing, Arce noted, San Diego, Calif.-based Arcturus intends to transfer its vaccine technology to Catalent this month and expects Catalent to manufacture the first batches of LUNAR-COV19 by June 2020. "Critically, Arcturus continues to anticipate initiation of Phase 1 testing of LUNAR-COV19 in the summer of 2020," Arce highlighted.

Catalent is to produce the vaccine at its biomanufacturing facility in Madison, Wisc. "This facility utilizes Catalent's flex-suite, a current good manufacturing practice manufacturing suite, that can produce batches at multiple scales and support Arcturus' proprietary mRNA manufacturing process," explained Arce.

Obtaining the vaccine from one facility domestically versus multiple entities worldwide should result in several benefits, Arce continued. They include easy development and production, accelerated delivery and improved costs. Arcturus believes Catalent can produce millions of doses of LUNAR-COV19 mRNA in 2020 and, if need be, hundreds of millions of doses each year subsequently for use globally.

Arce pointed out that LUNAR-COV19 differentiates itself from other similar vaccine candidates in that the technology and delivery platform behind it deliver an "extraordinarily low dose (perhaps 2 micrograms)" in "a potential single shot."

H.C. Wainwright has a Buy rating and a $62 per share price target on Arcturus, the stock of which is currently trading at about $42.12 per share.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from H.C. Wainwright & Co., Arcturus Therapeutics Holdings Inc., First Take, May 4, 2020

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Ed Arce, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst's household has a financial interest in the securities of Arcturus Therapeutics Holdings Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of April 30, 2020 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Arcturus Therapeutics Holdings Inc.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The firm or its affiliates received compensation from Arcturus Therapeutics Holdings Inc. for non-investment banking services in the previous 12 months.

The Firm or its affiliates did receive compensation from Arcturus Therapeutics Holdings Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Arcturus Therapeutics Holdings Inc. during the past 12 months.

The Firm does not make a market in Arcturus Therapeutics Holdings Inc. as of the date of this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

( Companies Mentioned: ARCT:NASDAQ, )

Recent strides in biotechnology offer the promise of new and innovative applications -- from edible vaccines to protein-based electronics components.